BASE10 and DNA Link Partners on Research to Support Authorization of Antibody Test at the Point of Care
illi News/10093080

CHICAGO, Nov. 26, 2020 /PRNewswire/ -- BASE10 Genetics and DNA Link today announced their collaboration on a research project to evaluate the usability of DNA Link's AccuFind COVID-19 IgG antibody test in a healthcare setting.

Although Covid-19 deaths and new confirmed cases continue to rise across nursing homes in the US, many of those infected do recover. This has led to growing interest in the relationship between antibodies and their protective value whether generated by previous Covid-19 exposure or by a vaccine, once available.

At present, most antibody tests on the market require samples to be sent to a lab for analysis. The extra cost and time associated has constrained population wide studies of SARS-CoV-2 antibodies.

"An antibody test that can be done at the point of care without the need for a lab can more quickly provide information clinicians and administrators need to make decisions for their nursing home patients and staff," says Dr. Michael Fang, BASE10 CEO.

More on illi News

• Who Will Win the 2025 WNBA Finals? OddsTrader Shares Live Betting Odds and Projections
• Naperville's Annual Public Safety Open House Set for Sept. 27
• Geeks5g Creative Marketing: The Powerhouse Behind Business Growth
• Agemin Unveils Breakthrough AI Model for Biometric Age Estimation, Setting New Standards in Online Child Safety
• Chicago: O'Hare International Airport Sets All-Time Passenger Record in July 2025

"This research is an important milestone in our efforts to expand access to antibody testing," says Elizabeth Freund, VP of Innovation at BASE10. "DNA Link's AccuFind performs very well in laboratory settings. The next logical step is to test its performance when used by healthcare professionals outside the lab. Many factors have the potential to affect test performance in lesser controlled settings so it's an ambitious goal to be sure. However, if FDA believes the data demonstrates its safety and effectiveness under these conditions, we'll be one step closer to FDA emergency use authorization for point of care use."

The study is set to launch in December.

About BASE10 Genetics, Inc.
BASE10 is a precision medicine company based in Chicago. BASE10's proprietary platform identifies precision diagnostics technologies with high potential for improving health outcomes, and creates turnkey, disease management programs that can be deployed at scale for insurance payors.

More on illi News

• The Hidden Triggers of Foreclosure Most Families Don't See Coming
• Strategic Partnerships with Defiant Space Corp and Emtel Energy USA Powerfully Enhance Solar Tech Leader with NASA Agreements: Ascent Solar $ASTI
• 120% Revenue Surge with Four Straight Profitable Quarters Signal a Breakout in the Multi-Billion Dollar Homebuilding Market: Innovative Designs $IVDN
• Leading Venture Capital Firms Recognize Wzzph Exchange's Technical Architecture and Security Framework as Industry Benchmark
• DivX Unveils Major DivX Software Update: Seamless Video Sharing and Customizable Playback Now Available

For more information about BASE10 Genetics and its solutions, contact [email protected].

About DNA Link, Inc.
DNA Link, Inc. is a leading genomic service corporation based in Korea with a focus on personalized medicine and new drug development. The company combines biotechnology with information & communications technology to support total analysis of genomic and clinical information to accelerate research and development in the field of bio-industry and genomic analysis industry.

For more information about DNA Link and its solutions, contact [email protected]

SOURCE BASE10 Genetics, Inc.

Related Links

https://www.base10genetics.com/

---

Show All News | Report Violation